Treatment of Early Avascular Necrosis of Femoral Head by Small Intestinal Submucosal Matrix With Peripheral Blood Stem Cells

Song, Huanjin; Lan, Bin; Cheng, Bin; Zhang, K.-F.; Yan, Hongwei; Wang, W.-Z.; Gao, Zhongyang

doi:10.1016/j.transproceed.2010.12.060

Cited by 13 publications

(24 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All preclinical studies utilized an animal model (8 rabbit [6,10,17,30-34], 2 dog [11,12] and 1 sheep model [4]). AVN was induced using methylprednisolone injection in 6 of the 11 studies [6,10,30-32,34].…”

Section: Resultsmentioning

confidence: 99%

“…AVN was induced using methylprednisolone injection in 6 of the 11 studies [6,10,30-32,34]. One model utilized liquid nitrogen to create AVN of the FH [17]. Three studies utilized a femoral neck osteotomy to induce AVN [11,12,33].…”

Section: Resultsmentioning

confidence: 99%

“…The type of SC implanted were variable yet may be classified into three groups: 1) bone marrow derived stem cells – concentrated, un-cultured bone marrow mononuclear cells (BMMNC), fresh (1 study) [6] or cryopreserved (1 study) [32], and mesenchymal stem cells obtained post BMMNC culture (4 studies) [11,12,30,33]; 2) adipose derived stem cells (2 studies) [10,34]; 3) other – peripheral blood hematopoietic SC (1 study) [17], cultured endothelial progenitor cells (EPC) (1 study) [31], and human immature dental pulp SC (1 study) [4] (Table 1). …”

Section: Resultsmentioning

confidence: 99%

“…SC can be obtained from a variety of sources, including autologous bone marrow [2,4,10,11,16,17], adipose tissue [10] and dental-pulp [4]. SC have been shown to promote bone formation [4,6,11,12] and neovascularization [6,11] in vitro.…”

Section: Introductionmentioning

confidence: 99%

“…Yan et al documented that stem cells implanted into the necrotic FH not only survive, but thrive and proliferate [15]. Although the pathogenesis of AVN is unclear [17] many hypothesize that SC work to improve early stage AVN potentially as a function of their critical role in the regulation and improvement of osteogenesis and angiogenesis [11,12]. Furthermore, it is thought that mesenchymal SC implanted into the necrotic FH may differentiate into osteoblasts or vascular endothelial cells, thereby promoting bone repair and regeneration [12].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Stem cell therapy for the treatment of early stage avascular necrosis of the femoral head: a systematic review

Lau

Perruccio

Evans

et al. 2014

BMC Musculoskelet Disord

View full text Add to dashboard Cite

BackgroundAvascular necrosis (AVN) of the femoral head (FH) is believed to be caused by a multitude of etiologic factors and is associated with significant morbidity in younger populations. Eventually, the disease progresses and results in FH collapse. Thus, a focus on early disease management aimed at joint preservation by preventing or delaying progression is key. The use of stem cells (SC) for the treatment of AVN of the FH has been proposed. We undertook a systematic review of the medical literature examining the use of SC for the treatment of early stage (precollapse) AVN of the FH, in both pre-clinical and clinical studies.MethodsData collected included: Pre-clinical studies – model of AVN, variety and dosage of SC, histologic and imaging analyses. Clinical studies – study design, classification and etiology of AVN, SC dosage and treatment protocol, incidence of disease progression, patient reported outcomes, volume of necrotic lesion and hip survivorship.ResultsIn pre-clinical studies, the use of SC uniformly demonstrated improvements in osteogenesis and angiogenesis, yet source of implanted SC was variable. In clinical studies, groups treated with SC showed significant improvements in patient reported outcomes; however hip survivorship was not affected. Discrepancies regarding dose of SC, AVN etiology and disease severity were present.ConclusionsRoutine use of this treatment method will first require further research into dose and quality optimization as well as confirmed improvements in hip survivorship.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Stem cell therapy for the treatment of early stage avascular necrosis of the femoral head: a systematic review

Lau

Perruccio

Evans

et al. 2014

BMC Musculoskelet Disord

View full text Add to dashboard Cite

show abstract

Critical assessment of the efficiency of CD34 and CD133 antibodies for enrichment of rabbit hematopoietic stem cells

Vašíček

Shehata

Schnabl

et al. 2018

Biotechnology Progress

View full text Add to dashboard Cite

Rabbits have many hereditary diseases common to humans and are therefore a valuable model for regenerative disease and hematopoietic stem cell (HSC) therapies. Currently, there is no substantial data on the isolation and/or enrichment of rabbit HSCs. This study was initiated to evaluate the efficiency of the commercially available anti-CD34 and anti-CD133 antibodies for the detection and potential enrichment of rabbit HSCs from peripheral blood. PBMCs from rabbit and human blood were labelled with different clones of anti-human CD34 monoclonal antibodies (AC136, 581, and 8G12) and rabbit polyclonal CD34 antibody (pCD34) and anti-human CD133 monoclonal antibodies (AC133 and 293C3). Flow cytometry showed a higher percentage of rabbit CD34 cells labelled by AC136 in comparison to the clone 581 and pCD34 (P < 0.01). A higher percentage of rabbit CD133 cells were also detected by 293C3 compared to the AC133 clone (P < 0.01). Therefore, AC136 clone was used for the indirect immunomagnetic enrichment of rabbit CD34 cells using magnetic-activated cell sorting (MACS). The enrichment of the rabbit CD34 cells after sorting was low in comparison to human samples (2.4% vs. 39.6%). PCR analyses confirmed the efficient enrichment of human CD34 cells and the low expression of CD34 mRNA in rabbit positive fraction. In conclusion, the tested antibodies might be suitable for detection, but not for sorting the rabbit CD34 HSCs and new specific anti-rabbit CD34 antibodies are needed for efficient enrichment of rabbit HSCs. © 2018 American Institute of Chemical Engineers Biotechnol. Prog., 2018 © 2018 American Institute of Chemical Engineers Biotechnol. Prog., 34:1278-1289, 2018.

show abstract

Combination Treatment of Biomechanical Support and Targeted Intra-arterial Infusion of Peripheral Blood Stem Cells Mobilized by Granulocyte-Colony Stimulating Factor for the Osteonecrosis of the Femoral Head: A Randomized Controlled Clinical Trial

Mao

Wang

et al. 2014

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Objective To determine the benefits of combination treatment with mechanical support and targeted intra-arterial infusion of peripheral blood stem cells (PBSCs) mobilized by granulocyte-colony stimulating factor (G-CSF) via the medial circumflex femoral artery on the progression of osteonecrosis of the femoral head (ONFH). Methods 55 patients (89 hips) with early and intermediate stage ONFH were recruited and randomly assigned to combination treatment or mechanical support treatment (control group). All hips received mechanical support treatment (porous tantalum rod implantation). Then, Hips in the combination treatment group were performed targeted intra-arterial infusion of PBSCs. At each follow-up, Harris hip score (HHS) and Association Research Circulation Osseous classification (ARCO) were used to evaluate the symptoms and progression of osteonecrosis. Total hip arthroplasty (THA) was assessed as an endpoint at each follow-up. Results At 36 months, 9 of the 41 hips (21.95%) in the control group progressed to clinical failure and underwent THA whereas only 3 of the 48 hips (6.25%) in the combination treatment group required THA(p=0.031). Kaplan-Meier survival analysis showed a significant difference in the survival time between the two groups (Log-rank test; p=0.025). Compared to the control group, combination treatment significantly improved the HHS at 36 months (p=0.003). At the final follow-up examination, radiological progression was noted in 13 of 41 hips (31.71%) for the control group, while only in 4 of 48 hips (8.33%) for the combination treatment group (p=0.005). The overall collapse rates were 15.15% (5 of 33 hips) and 8.11% (3 of 37 hips) in the control and combination treatment groups, respectively. Conclusions Targeted intra-arterial infusion of PBSCs is capable of enhancing the efficacy of biomechanical support in the treatment of ONFH. This clinical trial confirmed that the combination treatment might be a safe and feasible choice for the treatment of early or intermediate stages of ONFH.

show abstract

Treatment of Early Avascular Necrosis of Femoral Head by Small Intestinal Submucosal Matrix With Peripheral Blood Stem Cells

Cited by 13 publications

References 17 publications

Stem cell therapy for the treatment of early stage avascular necrosis of the femoral head: a systematic review

Stem cell therapy for the treatment of early stage avascular necrosis of the femoral head: a systematic review

Critical assessment of the efficiency of CD34 and CD133 antibodies for enrichment of rabbit hematopoietic stem cells

Combination Treatment of Biomechanical Support and Targeted Intra-arterial Infusion of Peripheral Blood Stem Cells Mobilized by Granulocyte-Colony Stimulating Factor for the Osteonecrosis of the Femoral Head: A Randomized Controlled Clinical Trial

Contact Info

Product

Resources

About